Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06261424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of a Supervised Rehabilitation Program on Disease Severity in Spastic Ataxias

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 18, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Université du Québec à Chicoutimi to Laval University
    • Collaborators: 11 to 10
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2024 to Feb 1, 2024
    • Site details revised at 5 of 5 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Spastic ataxias are a group of diseases causing symptoms such as walking difficulties and balance impairments that lead to a high risk of falls. No pharmacological treatments exist to treat these diseases. Unfortunately, little effort is made to develop non-pharmacological treatments specific to spastic ataxias despite the detrimental impact of the disease on several aspects of an individual's life and the high cost of falls for society each year. The three objectives of this project are: 1) to determine the effect of a 12-week rehabilitation program on disease severity as compared with usual care for individuals with spastic ataxias; 2) to identify which factors can help (or not) the implementation of the program in the clinical settings ("reel world"); and 3) to explore the cost-benefits of IMPACT \[rehabIlitation prograM for sPAstiC aTaxias\]. The team has developed the program to specifically target symptoms present in these patients and was previously pilot-tested. Based on the results obtained in this pilot project, positive effects are expected concerning the disease severity of participants. The investigators want, with this project, provide to health care professionals an option to offer better-suited services to people living with spastic ataxia worldwide.
Trial Details
NCT Number NCT06261424
Lead Sponsor Laval University
Collaborators: McGill University, Université de Sherbrooke, Université du Québec a Montréal, University of Calgary, Corporation de recherche et d'action sur les maladies héréditaires (CORAMH), Cégep de Jonquière, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-St-Jean, Muscular Dystrophy Canada, University of Alberta, Integrated University Health and Social Services Center of the Capitale-Nationale
Conditions
(from sponsor)		 Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay, Spastic Paraplegia 7
Related terms Spastic ataxia Charlevoix-Saguenay type, Spastic Paraplegia Type 7
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov